The present invention relates to uses of an EGFR/HER2 inhibitor combined with a pyrimidine-type anti-metabolic drug, and specifically, to uses of an EGFR/HER2 receptor tyrosine kinase inhibitor combined with pyrimidine-type anti-metabolic drug in the preparation of drugs for treating cancers.